ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Louis A. Lanza
Joe B. Putnam, Jr
Robert S. Benjamin
Jack A. Roth
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lanza, L. A.
Right arrow Articles by Roth, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lanza, L. A.
Right arrow Articles by Roth, J. A.

Ann Thorac Surg 1991;51:219-224
© 1991 The Society of Thoracic Surgeons

Articles

Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases

Louis A. Lanza, MD, Joe B. Putnam, Jr, MD*, Robert S. Benjamin, MD, Jack A. Roth, MD

Departments of Thoracic Surgery and Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas USA

Accepted for publication October 1, 1990.

* Address reprint requests to Dr Putnam, 1515 Holcombe Blvd, Box 109, Houston, TX 77030-4009.

Between 1979 and 1988, 26 patients with pulmonary metastases from adult soft-tissue sarcomas were treated with Adriamycin (doxorubicin hydrochloride), Cytoxan (cyclophosphamide), and DTIC before metastasectomy. Thirty-eight thoracotomies were performed with postoperative complications in 5 patients ([equation], 13.2%) and one postoperative death ([equation], 2.6%). Two patients had benign lesions at thoracotomy and were excluded from further survival analysis. The median survival of the remaining 24 patients after thoracotomy was 18.5 ± 5.9 months, and the actuarial 5-year survival was 22%. Five patients ([equation], 21%) achieved a clinically complete response with preoperative chemotherapy, but all had recurrence in the lung and underwent resection of pulmonary metastases. Seven patients ([equation], 29%) achieved a partial response and had residual disease resected at thoracotomy. Twelve patients ([equation], 50%) showed either no change or disease progression while receiving chemotherapy and were referred for resection. Postthoracotomy disease-free survival and postthoracotomy overall survival did not differ significantly between the three groups. One patient in the group showing no change or progression of disease while receiving chemotherapy is alive without recurrence 57 months after initial pulmonary metastasectomy. Chemotherapy can be used for the initial treatment of pulmonary metastases from adult soft-tissue sarcomas. However, survival after resection of pulmonary metastases cannot be accurately predicted based on the clinical response to preoperative chemotherapy.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
B. M. Burt, S. Ocejo, C. M. Mery, M. Dasilva, R. Bueno, D. J. Sugarbaker, and M. T. Jaklitsch
Repeated and Aggressive Pulmonary Resections for Leiomyosarcoma Metastases Extends Survival
Ann. Thorac. Surg., October 1, 2011; 92(4): 1202 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. M. Suri, C. Deschamps, S. D. Cassivi, F. C. Nichols III, M. S. Allen, C. D. Schleck, and P. C. Pairolero
Pulmonary Resection for Metastatic Malignant Fibrous Histiocytoma: An Analysis of Prognostic Factors
Ann. Thorac. Surg., November 1, 2005; 80(5): 1847 - 1852.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. Lee, C. H.R. Boasquevisque, M. M. Boglione, M. Hiratsuka, R. K. Scheule, J. D. Cooper, and G. A. Patterson
Isolated lung liposome-mediated gene transfer produces organ-specific transgenic expression
Ann. Thorac. Surg., September 1, 1998; 66(3): 903 - 907.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. Furrer, D. Lardinois, W. Thormann, H.-J. Altermatt, D. Betticher, J. Triller, D. Mettler, U. Althaus, M. E. Burt, and H.-B. Ris
Cytostatic Lung Perfusion by Use of an Endovascular Blood Flow Occlusion Technique
Ann. Thorac. Surg., June 1, 1998; 65(6): 1523 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. Furrer, D. Lardinois, W. Thormann, H. J. Altermatt, D. Betticher, T. Cerny, A. Fikrle, D. Mettler, U. Althaus, M. E. Burt, et al.
Isolated Lung Perfusion: Single-Pass System Versus Recirculating Blood Perfusion in Pigs
Ann. Thorac. Surg., May 1, 1998; 65(5): 1420 - 1425.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. Abolhoda, A. Brooks, S. Nawata, Y. Kaneda, H. Cheng, and M. E. Burt
Isolated Lung Perfusion With Doxorubicin Prolongs Survival in a Rodent Model of Pulmonary Metastases
Ann. Thorac. Surg., July 1, 1997; 64(1): 181 - 184.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
S. Nawata, A. Abolhoda, H. M. Ross, A. Brooks, and M. E. Burt
Sequential Bilateral Isolated Lung Perfusion in the Rat: An Experimental Model
Ann. Thorac. Surg., March 1, 1997; 63(3): 796 - 799.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. Nawata, N. Abecasis, H. M. Ross, A. Abolhoda, H. Cheng, K. S. Sachar, and M. E. Burt
ISOLATED LUNG PERFUSION WITH MELPHALAN FOR THE TREATMENT OF METASTATIC PULMONARY SARCOMA
J. Thorac. Cardiovasc. Surg., December 1, 1996; 112(6): 1542 - 1548.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. B. Ratto, S. Toma, D. Civalleri, G. C. Passerone, M. Esposito, D. Zaccheo, M. Canepa, P. Romano, R. Palumbo, F. De Cian, et al.
ISOLATED LUNG PERFUSION WITH PLATINUM IN THE TREATMENT OF PULMONARY METASTASES FROM SOFT TISSUE SARCOMAS
J. Thorac. Cardiovasc. Surg., September 1, 1996; 112(3): 614 - 622.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
B. Ng, S. N. Hochwald, and M. E. Burt
Isolated Lung Perfusion With Doxorubicin Reduces Cardiac and Host Toxicities Associated With Systemic Administration
Ann. Thorac. Surg., March 1, 1996; 61(3): 969 - 972.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
H.-Y. Wang, N. Bruce, D. Blumberg, J. L. Port, S. N. Hochwald, and M. E. Burt
Pulmonary artery perfusion of doxorubicin with blood flow occlusion: pharmacokinetics and treatment in a metastatic sarcoma model
Ann. Thorac. Surg., November 1, 1995; 60(5): 1390 - 1394.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. Weksler, B. Ng, J. T. Lenert, and M. E. Burt
Isolated single-lung perfusion: A study of the optimal perfusate and other pharmacokinetic factors
Ann. Thorac. Surg., September 1, 1995; 60(3): 624 - 629.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. L. Port, S. N. Hochwald, H.-Y. Wang, and M. E. Burt
Buthionine sulfoximine pretreatment potentiates the effect of isolated lung perfusion with doxorubicin
Ann. Thorac. Surg., August 1, 1995; 60(2): 239 - 244.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
B. Weksler, J. Lenert, B. Ng, and M. Burt
Isolated single lung perfusion with doxorubicin is effective in eradicating soft tissue sarcoma lung metastases in a rat model
J. Thorac. Cardiovasc. Surg., January 1, 1994; 107(1): 50 - 54.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
B. Weksler, N. Bruce, J. T. Lenert, and M. E. Burt
Isolated single-lung perfusion with doxorubicin is pharmacokinetically superior to intravenous injection
Ann. Thorac. Surg., August 1, 1993; 56(2): 209 - 214.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1991 by The Society of Thoracic Surgeons.